Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta.

Slides:

Advertisements

Similar presentations

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation.

Advertisements

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective.

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission Daniela Damiani,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients:

Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results Joseph Pidala, Jongphil.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus- I–negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective.

Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of.

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease Joseph Pidala, MD, PhD, Francisca Beato, BS,

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement Jun Aoki, Ken.

Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non- Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17 Jinichi.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Mohamed A. Kharfan-Dabaja, Yasser R. Abou Mourad, Hugo F

Blood and Marrow Transplant Handbook

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Mammen Chandy Biology of Blood and Marrow Transplantation

Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation Robertson Parkman,

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation Janelle.

High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta Di Nicola, Teresa Field, Melissa Alsina, Ernesto Ayala, William Janssen, Mohamed A. Kharfan- Dabaja, Leonel Ochoa, Lia Perez, Janelle Perkins, Jyoti Raychaudhuri, Hugo Fernandez, Claudio Anasetti Biology of Blood and Marrow Transplantation Volume 17, Issue 10, Pages 1505-1511 (October 2011) DOI: 10.1016/j.bbmt.2011.02.011 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of nonrelapse mortality according to age <35 (solid line) vs. age ≥35 (dashed line), P = .73. Biology of Blood and Marrow Transplantation 2011 17, 1505-1511DOI: (10.1016/j.bbmt.2011.02.011) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of relapse, stratified according to remission status at time of transplant (solid line = CR1, dashed line = more advanced disease, including CR2 and -3, and primary induction failure), P = .036 for comparison. Biology of Blood and Marrow Transplantation 2011 17, 1505-1511DOI: (10.1016/j.bbmt.2011.02.011) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Overall survival, stratified by remission status at time of transplant (dashed line = CR1, solid line = more advanced disease), log-rank P = .06. Biology of Blood and Marrow Transplantation 2011 17, 1505-1511DOI: (10.1016/j.bbmt.2011.02.011) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Relapse-free survival from date of transplantation, stratified by remission status (dashed line = CR1, solid line = more advanced disease), log-rank P = .09. (B) Relapse-free survival from date of transplantation, stratified by age (solid line = age <35, dashed line = age ≥35), log-rank P = .79. Biology of Blood and Marrow Transplantation 2011 17, 1505-1511DOI: (10.1016/j.bbmt.2011.02.011) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions